Diagnosis and prognosis are supported by integrated assessment of next-generation sequencing in chronic myeloid malignancies. A real-life study
Open Access
- 2 April 2020
- journal article
- research article
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 106 (3), 701-707
- https://doi.org/10.3324/haematol.2019.242677
Abstract
Next generation sequencing (NGS) investigates for somatic mutations. The utility of incorporating routine sequencing to guide diagnosis and therapeutic decisions remains challenging. We report an observational multicentric study that aimed to assess the impact of somatic mutations testing by NGS in a real-life setting of chronic myeloid malignancies (CMM). A total of 177 patients were enrolled, partitioned in two overlapping groups. In group A (N=94), the indication was to search for clonal hematopoiesis (CH), in a context of suspected myelodysplastic syndrome or myeloproliferative neoplasia. In group B (N=95), the theranostic impact of somatic mutations was studied. A panel of 34 genes was applied on DNA extracted from blood or bone marrow samples. Within group A, the detection of CH comforted the diagnosis of CMM for 31 patients while absence of CH ruled out the suspected diagnosis in 47 patients. Within group B, NGS identified prognostic somatic mutations in 32 patients, with a therapeutic impact in 18 cases. The use of NGS in daily practice was found here to be useful for an integrated final diagnosis in 83% of the patients through the presence or absence of somatic mutations. Moreover, exploration for somatic mutations had a prognostic impact that led to treatment modification in 19% of the cases. This study outlines the fact that adequate prescription of these new investigations may have a significant positive medico-economic impact by allowing appropriate management of the patients.This publication has 27 references indexed in Scilit:
- Clinical and biological implications of driver mutations in myelodysplastic syndromesBlood, 2013
- Prognostic Score Including Gene Mutations in Chronic Myelomonocytic LeukemiaJournal of Clinical Oncology, 2013
- Mutations and prognosis in primary myelofibrosisLeukemia, 2013
- Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemiaBlood, 2013
- Revised International Prognostic Scoring System for Myelodysplastic SyndromesBlood, 2012
- Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasmsBlood, 2011
- Clinical Effect of Point Mutations in Myelodysplastic SyndromesThe New England Journal of Medicine, 2011
- Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosisBlood, 2010
- Using Real-World Data for Coverage and Payment Decisions: The ISPOR Real-World Data Task Force ReportValue in Health, 2007
- Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conferenceLeukemia Research, 2007